Study Summary
This trial is testing a new imaging agent to see if it can better detect prostate cancer, especially when PSA levels are low.
- Prostate Cancer
- Adenocarcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Ga-HBED-iPSMA PET with CT or MRI
1 of 2
Ga-HBED-iPSMA PET with MRI
1 of 2
Active Control
1171 Total Participants · 2 Treatment Groups
Primary Treatment: Ga-HBED-iPSMA PET with CT or MRI · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 17th, 2021
Last Reviewed: November 21st, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.